EA201200489A1 - Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата - Google Patents

Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата

Info

Publication number
EA201200489A1
EA201200489A1 EA201200489A EA201200489A EA201200489A1 EA 201200489 A1 EA201200489 A1 EA 201200489A1 EA 201200489 A EA201200489 A EA 201200489A EA 201200489 A EA201200489 A EA 201200489A EA 201200489 A1 EA201200489 A1 EA 201200489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
crystal
prevention
treatment
epalrestate
Prior art date
Application number
EA201200489A
Other languages
English (en)
Other versions
EA023435B1 (ru
Inventor
Изабель Калофонос
Г. Патрик Стэнли
Вильям Мартин-Дойл
Димитрис Калофонос
Джефри С. Сталс
Трэвис Л. Хьюстон
Original Assignee
Бионевия Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионевия Фармасьютикалс, Инк. filed Critical Бионевия Фармасьютикалс, Инк.
Publication of EA201200489A1 publication Critical patent/EA201200489A1/ru
Publication of EA023435B1 publication Critical patent/EA023435B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области фармакологии, в частности, к фармацевтической композиции, включающей новый холиновый сокристалл эпалрестата 5-[(1Z.2Е)-2-метил-3-фенилпропенилиден]-4-оксо-2-тиоксо-3-тиазолидинуксусной кислоты. Получают новый сокристалл холина в соответствии с различными вариантами изобретения. Изобретение связано также с терапевтическим применением фармацевтической композиции, включающей новый сокристалл холина для лечения и/или профилактики различных заболеваний, включая лечение и/или профилактику осложнений диабета, лечение и/или профилактику гомоцистинурии, связанной с уменьшением уровней гомоцистеина в сыворотке крови, ингибирование альдозоредуктазы, а также создание кардиопротекторного эффекта у пациентов без диабета.
EA201200489A 2008-09-06 2009-09-03 Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата EA023435B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9490408P 2008-09-06 2008-09-06

Publications (2)

Publication Number Publication Date
EA201200489A1 true EA201200489A1 (ru) 2013-01-30
EA023435B1 EA023435B1 (ru) 2016-06-30

Family

ID=41797847

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100245A EA016904B1 (ru) 2008-09-06 2009-09-03 Новый холиновый сокристалл эпалрестата
EA201200489A EA023435B1 (ru) 2008-09-06 2009-09-03 Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201100245A EA016904B1 (ru) 2008-09-06 2009-09-03 Новый холиновый сокристалл эпалрестата

Country Status (17)

Country Link
US (3) US8906948B2 (ru)
EP (1) EP2326632B8 (ru)
CN (1) CN102216281B (ru)
AU (1) AU2009288037B2 (ru)
CA (1) CA2738231C (ru)
CY (1) CY1119752T1 (ru)
DK (1) DK2326632T3 (ru)
EA (2) EA016904B1 (ru)
ES (1) ES2639019T3 (ru)
GB (1) GB2476202B (ru)
HU (1) HUE034456T2 (ru)
LT (1) LT2326632T (ru)
PL (1) PL2326632T3 (ru)
PT (1) PT2326632T (ru)
SI (1) SI2326632T1 (ru)
UA (1) UA106209C2 (ru)
WO (1) WO2010028132A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
ES2639019T3 (es) 2008-09-06 2017-10-25 Bionevia Pharmaceuticals Inc. Nuevo cocristal de colina de epalrestat
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP3042654A1 (en) 2011-01-20 2016-07-13 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
ITMI20120586A1 (it) 2012-04-11 2013-10-12 Milano Politecnico Co-cristalli di 3-iodiopropinil butilcarbammato
CN103951634B (zh) * 2014-05-07 2016-06-08 浙江东亚药业股份有限公司 一种依帕司他结晶盐水合物和羟基哌啶共晶物及其制备方法和应用
AU2015267312B2 (en) * 2014-05-27 2018-06-28 Artificial Cell Technologies, Inc. Automated layer by layer construction of multilayer coated cores by TFF
EP3947391A1 (en) 2019-04-01 2022-02-09 Applied Therapeutics Inc. Inhibitors of aldose reductase
CA3136100A1 (en) * 2019-05-07 2020-11-12 Stephan L. ZUCHNER Treatment and detection of inherited neuropathies and associated disorders
CN113277962B (zh) * 2021-06-01 2023-02-07 天津大学 依帕司他-二甲双胍盐水合物及其制备方法和应用
CN113336718B (zh) * 2021-06-01 2023-02-28 天津大学 依帕司他-二甲双胍盐及其制备方法和应用
CN113292511B (zh) * 2021-06-01 2022-11-25 天津大学 依帕司他-二甲双胍盐乙醇水双溶剂化物及制备方法和应用
CN113354596B (zh) * 2021-06-01 2022-11-29 天津大学 依帕司他-二甲双胍盐丙酮溶剂化物及制备方法和应用
CN115947699B (zh) * 2023-01-16 2024-01-19 威海海洋职业学院 以烟酰胺为前驱体的依帕司他共晶及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO129043B (ru) 1968-02-16 1974-02-18 Fujisawa Pharmaceutical Co
JPS5740478A (en) 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
JPS5852220A (ja) 1981-09-24 1983-03-28 Fujisawa Pharmaceut Co Ltd 血清尿酸値低下剤
JPS6251955A (ja) 1985-08-22 1987-03-06 Sansei Seiyaku Kk 飼料組成物
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
GB9526264D0 (en) 1995-12-21 1996-02-21 Knoll Ag Medical treatment
EP0906104A4 (en) 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
AU2002215160A1 (en) * 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP3547010B1 (ja) * 2002-12-27 2004-07-28 小野薬品工業株式会社 ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の結晶の製造方法およびその製剤
WO2004064762A2 (en) 2003-01-21 2004-08-05 S.S.C.I. Inc. Novel cocrystallization
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2548281C (en) * 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP2005298424A (ja) * 2004-04-13 2005-10-27 Sawai Pharmaceutical Co Ltd エパルレスタット結晶の製造方法
JP4892821B2 (ja) 2004-09-30 2012-03-07 大日本印刷株式会社 エパルレスタット製造法
JP4892915B2 (ja) * 2005-10-04 2012-03-07 大日本印刷株式会社 エパルレスタット製造法
US20110275695A1 (en) 2008-06-13 2011-11-10 Bionevia Pharmaceuticals, Inc. Crystalline forms of zotepine hydrochloride
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
WO2010011926A2 (en) 2008-07-25 2010-01-28 Bionevia Pharmaceuticals, Inc. A novel betaine cocrystal of epalrestat
WO2010011922A2 (en) 2008-07-25 2010-01-28 Bionevia Pharmaceuticals, Inc. Novel crystalline salts of epalrestat
ES2639019T3 (es) 2008-09-06 2017-10-25 Bionevia Pharmaceuticals Inc. Nuevo cocristal de colina de epalrestat

Also Published As

Publication number Publication date
EA201100245A1 (ru) 2011-08-30
ES2639019T3 (es) 2017-10-25
PL2326632T3 (pl) 2017-10-31
US9611234B2 (en) 2017-04-04
HUE034456T2 (en) 2018-02-28
SI2326632T1 (sl) 2017-11-30
DK2326632T3 (en) 2017-09-18
GB2476202B (en) 2012-04-11
WO2010028132A2 (en) 2010-03-11
WO2010028132A3 (en) 2010-06-17
US20110275682A1 (en) 2011-11-10
US8906948B2 (en) 2014-12-09
AU2009288037B2 (en) 2014-08-14
GB2476202A (en) 2011-06-15
US20150057319A1 (en) 2015-02-26
CY1119752T1 (el) 2018-06-27
EP2326632B1 (en) 2017-05-31
LT2326632T (lt) 2017-09-25
EP2326632A2 (en) 2011-06-01
AU2009288037A1 (en) 2010-03-11
US10464912B2 (en) 2019-11-05
EP2326632B8 (en) 2017-08-09
EA016904B1 (ru) 2012-08-30
CA2738231C (en) 2015-04-07
CN102216281B (zh) 2014-11-05
US20170174643A1 (en) 2017-06-22
CN102216281A (zh) 2011-10-12
EA023435B1 (ru) 2016-06-30
CA2738231A1 (en) 2010-03-11
UA106209C2 (en) 2014-08-11
PT2326632T (pt) 2017-09-05
GB201105528D0 (en) 2011-05-18
EP2326632A4 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
EA201200489A1 (ru) Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата
EA201100246A1 (ru) Новый бетаиновый сокристалл эпалрестата
Ma et al. Sirt1 is essential for resveratrol enhancement of hypoxia-induced autophagy in the type 2 diabetic nephropathy rat
EA201100778A1 (ru) Гетероциклические замещенные соединения в качестве ингибиторов hif
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
EA201070656A1 (ru) Способ задержки начала проявления клинически определенного рассеянного склероза
WO2011056985A3 (en) Substituted heterocyclic compounds
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
EA200971053A1 (ru) Способы лечения кожных язв
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
BR112014012815A8 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
ATE447948T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE486595T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur senkung der lipid- und blutzuckerspiegel
EA201100623A1 (ru) Сульфоксиминзамещенные анилинопиримидиновые производные в качестве cdk ингибиторов, их получение и применение в качестве лекарственных средств
ATE457729T1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis

Legal Events

Date Code Title Description
QB4A Registration of a licence in a contracting state
QZ4A Registered corrections and amendments in a licence
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM